Cargando…
Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines is under investigation. Data on early virological response are limited. To iden-tify potential predictors of antibody durability, circulating antibody levels were longitudinally ex-plored in healthcare...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402545/ https://www.ncbi.nlm.nih.gov/pubmed/34452038 http://dx.doi.org/10.3390/vaccines9080913 |
_version_ | 1783745815519428608 |
---|---|
author | Cocomazzi, Giovanna Piazzolla, Valeria Squillante, Maria Maddalena Antinucci, Stefano Giambra, Vincenzo Giuliani, Francesco Maiorana, Alberto Serra, Nicola Mangia, Alessandra |
author_facet | Cocomazzi, Giovanna Piazzolla, Valeria Squillante, Maria Maddalena Antinucci, Stefano Giambra, Vincenzo Giuliani, Francesco Maiorana, Alberto Serra, Nicola Mangia, Alessandra |
author_sort | Cocomazzi, Giovanna |
collection | PubMed |
description | Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines is under investigation. Data on early virological response are limited. To iden-tify potential predictors of antibody durability, circulating antibody levels were longitudinally ex-plored in healthcare workers included in a follow-up program for SARS-CoV-2 infection. Meth-ods: Subjects meeting the inclusion criteria signed an informed consent. Serum samples were col-lected at baseline, before the first BNT162b2 vaccine, at days 7, 21, 31, 90, and 180 days after the first dose. Serological evaluation was performed by QuantiVac Euroimmune anti-S1 antibody as-say. Only subjects followed-up until day 90 are here considered. Results: Of 340 taken into consid-eration, 265 subjects were naive, and 75 COVID-19 experienced. The former showed a progres-sive increase in their antibody levels before day 90 decline, while the latter showed antibody levels reaching a plateau at day 7 and slightly declining at day 90. All showed antibody levels higher than the assay cut-off at day 31 and 90. Among naive, 108 had an early response whose predic-tors were younger age and female gender (OR 0.94, 95% CI 0.91–0.96, p < 0.0001; and OR 2.58, 95% CI 1.48–4.51, p = 0.0009). Naive subjects experienced a day 30/90 decline in antibody levels, whereas experienced did not. Early response was an independent predictor of higher day 30/90 antibody levels decline (OR = 2.05, 95% CI 1.04–4.02; p = 0.037). Conclusions: Our results suggest that in healthcare workers early response might be inversely associated with antibody levels 90 days after BNT162b2 vaccine. |
format | Online Article Text |
id | pubmed-8402545 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84025452021-08-29 Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers Cocomazzi, Giovanna Piazzolla, Valeria Squillante, Maria Maddalena Antinucci, Stefano Giambra, Vincenzo Giuliani, Francesco Maiorana, Alberto Serra, Nicola Mangia, Alessandra Vaccines (Basel) Article Purpose: Clinical significance and durability of serological response after mRNA COVID-19 vaccines is under investigation. Data on early virological response are limited. To iden-tify potential predictors of antibody durability, circulating antibody levels were longitudinally ex-plored in healthcare workers included in a follow-up program for SARS-CoV-2 infection. Meth-ods: Subjects meeting the inclusion criteria signed an informed consent. Serum samples were col-lected at baseline, before the first BNT162b2 vaccine, at days 7, 21, 31, 90, and 180 days after the first dose. Serological evaluation was performed by QuantiVac Euroimmune anti-S1 antibody as-say. Only subjects followed-up until day 90 are here considered. Results: Of 340 taken into consid-eration, 265 subjects were naive, and 75 COVID-19 experienced. The former showed a progres-sive increase in their antibody levels before day 90 decline, while the latter showed antibody levels reaching a plateau at day 7 and slightly declining at day 90. All showed antibody levels higher than the assay cut-off at day 31 and 90. Among naive, 108 had an early response whose predic-tors were younger age and female gender (OR 0.94, 95% CI 0.91–0.96, p < 0.0001; and OR 2.58, 95% CI 1.48–4.51, p = 0.0009). Naive subjects experienced a day 30/90 decline in antibody levels, whereas experienced did not. Early response was an independent predictor of higher day 30/90 antibody levels decline (OR = 2.05, 95% CI 1.04–4.02; p = 0.037). Conclusions: Our results suggest that in healthcare workers early response might be inversely associated with antibody levels 90 days after BNT162b2 vaccine. MDPI 2021-08-16 /pmc/articles/PMC8402545/ /pubmed/34452038 http://dx.doi.org/10.3390/vaccines9080913 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Cocomazzi, Giovanna Piazzolla, Valeria Squillante, Maria Maddalena Antinucci, Stefano Giambra, Vincenzo Giuliani, Francesco Maiorana, Alberto Serra, Nicola Mangia, Alessandra Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers |
title | Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers |
title_full | Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers |
title_fullStr | Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers |
title_full_unstemmed | Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers |
title_short | Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers |
title_sort | early serological response to bnt162b2 mrna vaccine in healthcare workers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402545/ https://www.ncbi.nlm.nih.gov/pubmed/34452038 http://dx.doi.org/10.3390/vaccines9080913 |
work_keys_str_mv | AT cocomazzigiovanna earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers AT piazzollavaleria earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers AT squillantemariamaddalena earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers AT antinuccistefano earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers AT giambravincenzo earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers AT giulianifrancesco earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers AT maioranaalberto earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers AT serranicola earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers AT mangiaalessandra earlyserologicalresponsetobnt162b2mrnavaccineinhealthcareworkers |